Insider buying last 90 days
No open-market insider purchases were filed for ABVX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Abivax shares have declined 31.2% over the last three months and remain below their 20-day, 50-day, and 200-day moving averages, reflecting a continued bearish configuration despite a modest midday rebound this week. The stock has also been cited among the better performers in the SBF 120 after an earlier quarterly drop of nearly 24%, and the company has confirmed its participation in a series of fall investor conferences running from 9 November through 3 December, including a presentation in Frankfurt on 23 November.
Abivax closed at $87.00, up 1.5% on the day, but sits well below its 50-day average of $96.67 and 200-day average of $113.11, with the 50-day itself below the 200-day. The GekkoIndex reads 61.2, placing the stock in the Accumulation zone, while the price remains 23.1% below the Gekko Fair Value of $113.08.
The next earnings report is scheduled for 21 December 2026, 41 days out, placing it outside a typical 20-trading-day holding window; the prior report on 21 September showed an actual loss of $1.71 per share against an estimate of -$1.03, with a reaction of -6.4%. No insider, Congress, or unusual options activity appears in the respective 90-day and 30-day windows. Seasonality over the past three years shows a mean 20-day return of -3.5%, with gains in only 1 of those periods, a pattern worth noting alongside the upcoming investor conference schedule.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Abivax scores 3 supportive, 0 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive0 mixed2 headwinds
Below 50 and 200-day
Close $87.58 is below the 50-day ($94.85) and 200-day ($112.57) averages, and the 50-day is below the 200-day.
See the chart60.3, Accumulation
Reading 60.3 is in the Accumulation zone.
See the GekkoIndex21.8% below
Price is 21.8% below Gekko Fair Value (more than 5% below).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 36 days
Next report Dec 21, 2026, 36 days away — outside a typical 20-trading-day hold.
See earnings−7.2% on average
From this point in the calendar, the next 20 trading days averaged −7.2% over 3 years, rising in 1 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Abivax closed at $87.58 on Nov 13, 2026, −15.3% over the past year, inside a 52-week range of $69.81 to $148.83.
Use the left and right arrow keys to read daily values.
Put ABVX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Abivax works on developing drug candidates aimed at inflammatory, infectious, and oncological conditions. Its most advanced program centers on a compound called ABX464, which has been studied for ulcerative colitis, Crohn's Disease, and COVID-19, with additional testing in rheumatoid arthritis and earlier work showing viral remission results in HIV patients. The company is also progressing a second candidate, ABX 196, designed to stimulate immune response, in trials targeting hepatocellular cancer.
Beyond its core pipeline, Abivax runs research programs directed at Dengue fever, influenza, and respiratory syncytial virus. Its work is supported by license arrangements with French research institutions, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie, connecting its drug development efforts to established scientific bodies.
Abivax was established in 2013 and is headquartered in Paris, France. Its shares trade under the ticker ABVX.
Abivax’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 60.3, in the Accumulation zone, down 2.6 points over five sessions.
Down 2.6 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 46 | +2.2% | +1.9% | ||
| Accumulation (current zone) | 265 | Not available | |||
| Neutral | 295 | −1.6% | +20.0% | ||
| Distribution | 44 | Not available | |||
| Selling | 5 | Too few readings yet | |||
Average ABVX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
Abivax trades 21.8% below Gekko Fair Value of $112.05, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Abivax shares are worth, recalculated every trading day.
$112.05
Gekko Fair Value, Nov 14, 2026
21.8% Undervalued
At the end of Aug 2026 the price was 26.1% below the estimate.
No open-market insider purchases were filed for Abivax, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for ABVX in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in ABVX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
1of the funds Gekko tracks holds ABVX.
Abivax reports on Dec 21, 2026 (36 days away), and beat the EPS estimate in 4 of its last 8 reports.
Dec 21, 2026
36 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Sep 21, 2026 | −$1.71 est −$1.03 | $1.37M est $799K | −6.4% |
| May 22, 2026 | −$0.71 est −$0.81 | $1.51M est $401K | +1.9% |
| Mar 23, 2026 | −$1.18 est −$1.04 | $515K est $1.80M | −8.5% |
| Dec 15, 2025 | −$2.47 est −$0.79 | $2.40M est $1.35M | −11.6% |
| Sep 8, 2025 | −$0.89 est −$0.95 | $1.33M est $1.35M | +1.4% |
| Jun 2, 2025 | −$0.95 est −$0.76 | $1.16M est $3.35M | +28.6% |
| Mar 24, 2025 | −$0.81 est −$1.29 | $6.37M est $2.83M | −0.5% |
| Nov 14, 2024 | −$0.70 est −$0.70 | — est $3.59M | −6.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Abivax is $163.58, +86.8% from the last close, from 8 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 8 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 21 | Piper Sandler | $175 | +99.8% |
| Oct 20 | Barclays | $148 | +69.0% |
| Oct 20 | Guggenheim | $175 | +99.8% |
| Oct 1 | BTIG | $175 | +99.8% |
| Sep 28 | Morgan Stanley | $180 | +105.5% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Abivax averaged −7.2% across the last 3 years, rising in 1 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −2.2% | 1 of 3 |
| Next 10 trading days | −4.9% | 1 of 3 |
| Next 15 trading days | −6.5% | 1 of 3 |
| Next 20 trading days | −7.2% | 1 of 3 |
| Next 30 trading days | −1.6% | 1 of 3 |
For scale, ABVX’s typical 20-trading-day move in either direction is about 10.8%.
Abivax’s market cap is $7.52B and revenue of $4.67M over the last twelve months.
Coverage of Abivax this week reads positive: 3 positive, 3 neutral and 2 negative headlines.
Abivax’s market cap is $7.52B at the Nov 13, 2026 close of $87.58, with 87.54M shares outstanding.
The consensus analyst 12-month price target for Abivax is $163.58, +86.8% from the last close. Of the 8 firms that rated the stock in the last 90 days, 7 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Abivax is undervalued: the Nov 13, 2026 close of $87.58 is 21.8% below Gekko Fair Value of $112.05. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Abivax is expected to report on Dec 21, 2026 (36 days away). Analysts expect earnings of −$0.92 per share on revenue of $923K. Abivax beat the earnings estimate in 4 of its last 8 reports, moving 8.2% on average across the report.
Abivax’s 52-week high is $148.83 and its 52-week low is $69.81; it closed at $87.58 on Nov 13, 2026, −15.3% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and earnings risk) and 2 as headwinds (trend and seasonality). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.